v3.22.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Grant and contract revenue $ 50,981 $ 459,494 $ 263,399 $ 998,139
Operating expenses:        
Research and development 4,726,517 4,216,294 8,659,864 7,622,542
General and administrative 4,890,544 2,853,265 8,667,167 7,620,910
Amortization of intangible asset 350,000   350,000  
Change in fair value of contingent consideration (203,000) 105,000 (224,000) 111,000
Total operating expenses 9,764,061 7,174,559 17,453,031 15,354,452
Loss from operations (9,713,080) (6,715,065) (17,189,632) (14,356,313)
Change in fair value of warrant liability 1,511 4,679 9,290 (4,023)
Interest income 175,173 176,798 295,875 371,963
Unrealized loss on available-for-sale securities (595,038) (56,071) (1,431,631) (202,384)
Other expense, net (132,476) (30,917) (137,610) (52,959)
Total non-operating (loss) income (550,830) 94,489 (1,264,076) 112,597
Net loss before income taxes (10,263,910) (6,620,576) (18,453,708) (14,243,716)
Net loss (10,263,910) (6,620,576) (18,453,708) (14,243,716)
Net loss - non-controlling interest (106,624) (77,379) (175,835) (168,341)
Net loss attributable to NightHawk Biosciences, Inc. $ (10,157,286) $ (6,543,197) $ (18,277,873) $ (14,075,375)
Net loss per share, basic (in dollars per share) $ (0.40) $ (0.26) $ (0.71) $ (0.57)
Net loss per share, diluted (in dollars per share) $ (0.40) $ (0.26) $ (0.71) $ (0.57)
Weighted-average common shares outstanding, basic (in shares) 25,602,965 25,137,466 25,598,481 24,671,281
Weighted-average common shares outstanding, diluted (in shares) 25,602,965 25,137,466 25,598,481 24,671,281
Comprehensive loss:        
Net loss $ (10,263,910) $ (6,620,576) $ (18,453,708) $ (14,243,716)
Unrealized gain on foreign currency translation 149,855 26,661 94,586 44,929
Total comprehensive loss (10,114,055) (6,593,915) (18,359,122) (14,198,787)
Comprehensive loss attributable to non-controlling interest (106,624) (77,379) (175,835) (168,341)
Comprehensive loss - NightHawk Biosciences, Inc. $ (10,007,431) $ (6,516,536) $ (18,183,287) $ (14,030,446)

Source